etoposide IV

P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed

P2, N=120, Not yet recruiting, National Cancer Institute, Egypt | Initiation date: Jan 2026 --> Apr 2026

P2/3, N=25, Recruiting, Medical University Of Lodz | Not yet recruiting --> Recruiting

P3, N=300, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting

P1, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2026 --> Apr 2027

P2, N=26, Active, not recruiting, M.D. Anderson Cancer Center | N=40 --> 26 | Recruiting --> Active, not recruiting

P1, N=21, Active, not recruiting, RayzeBio, Inc. | N=49 --> 21 | Trial completion date: Mar 2029 --> Jul 2027 | Recruiting --> Active, not recruiting

P1/2, N=25, Recruiting, Beijing Tongren Hospital

Disease stabilization was achieved using cadonilimab, apatinib, and ifosfamide/etoposide...An individualized, multimodal treatment approach may extend survival. scRNA-seq provides valuable insights into the molecular landscape of MTT and hold promise for guiding precision therapy in the future.

Postoperatively, she was treated with an Ewing sarcoma‑based chemotherapy protocol (vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide (VDC/IE)), but unfortunately, she died 10 months after surgery. While on one hand, among adolescents, fertility preservation poses an additional ethical and therapeutic challenge, on the other hand, rapid, individualised decision‑making is also required to prevent clinical deterioration. This case highlights the diagnostic and therapeutic dilemmas faced, the need to consider PNET in the differential diagnosis of aggressive uterine masses even in adolescents, the important role of ancillary testing like IHC and molecular studies for a definitive diagnosis and the difficulties in balancing life‑saving surgery and fertility preservation when disease is advanced.